观察硼替佐米联合化疗方案治疗多发性骨髓瘤患者的临床疗效及对生存率的影响

To observe the clinical efficacy of bortezomib combined with chemotherapy in the treatment of patients with multiple myeloma and its impact on survival

目的探究以硼替佐米为基础的化疗方案治疗多发性骨髓瘤(multiple myeloma,MM)的临床疗效及对患者生存率的影响,并评估其临床应用价值。方法选取2016年1月至2019年6月本院及南京鼓楼医院收治的73例MM患者,根据化疗方案的不同分为对照组(n=36)和观察组(n=37)。对照组采用长春地辛+阿霉素+地塞米松联合化疗方案,观察组采用硼替佐米+环磷酰脂+地塞米松。比较两组临床疗效和治疗后随访3、6、9、12个月的生存率。结果观察组总有效率高于对照组(P<0.05)。治疗后随访6、9及12个月,观察组生存率均高于对照组(P<0.05)。结论临床针对MM患者采用以硼替佐米为基础的化疗方案施治疗,临床疗效显著,能显著提高患者生存率。

Objective To explore the clinical application value of bortezomib-based chemotherapy regimens for the treatment of multiple myeloma(multiple myeloma,MM)and its impact on patient survival.Methods From January 2016 to June 2019,73 MM patients admitted to our hospital and Nanjing Gulou Hospital were selected and they were divided into control group(n=36)and observation group(n=37)according to the different chemotherapy regimens.The control group was treated with vinoresin+adriamycin+dexamethasone combined chemotherapy,and the observation group was treated with bortezomib+cyclophosphamide+dexamethasone.The total clinical effective rates and the survival rates at 3 months,6 months,9 months and 12 months follow up after treatment between the two groups were compared.Results The clinical total effective rate of the observation group was significantly higher than that of the control group(P<0.05).The survival rate of the observation group was respectively higher than that of the control group when the follow-up was in 6 months,9 months and 12 months after treatment(P<0.05).Conclusion It appears significant clinical efficacy adopting the treatment with bortezomib-based chemotherapy regimen for MM patients in clinic,and can significantly improve the survival rates of patients.